Aileron Therapeutics to Present at Upcoming Investor Conferences
Aileron Therapeutics (Nasdaq: ALRN) announced that Dr. Manuel Aivado will present a company overview at two upcoming virtual conferences: the H.C. Wainwright BIOCONNECT Conference from January 10-12, 2022, and the Emerging Growth Conference on January 5, 2022. The H.C. Wainwright presentation will be available on-demand starting January 10 at 7:00 a.m. ET. Aileron's ALRN-6924 is a first-in-class chemoprotective agent targeting p53-mutated cancers, aiming to improve chemotherapy tolerability while preserving healthy cells.
- None.
- None.
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients, is pleased to announce that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will provide a company overview and business update at the H.C. Wainwright BIOCONNECT Conference, which will be held virtually January 10th – 12th and the Emerging Growth Conference, which will be held virtually on January 5th. Details of the upcoming Aileron presentations are as follows:
H.C. Wainwright BIOCONNECT Conference
Date/Time: The presentation will be available on-demand beginning on Monday, January 10, 2022 at 7:00 a.m. ET.
A recorded webcast of the presentation will be archived under the Investors and Media section of Aileron’s website at https://investors.aileronrx.com/ for 30 days following the event.
Emerging Growth Conference
Date: Wednesday, January 5, 2022
Time: 12:45 p.m. ET
An interactive question-and-answer session with Dr. Aivado will follow the presentation.
Register here to watch the presentation.
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com.
About Aileron Therapeutics
Aileron is a clinical stage chemoprotection oncology company focused on fundamentally transforming the experience of chemotherapy for cancer patients. ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, in which we exclusively focus on treating patients with p53-mutated cancers. Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy while ensuring we do not protect cancer cells. As a result, healthy cells are spared from chemotherapeutic destruction while chemotherapy continues to kill cancer cells. By reducing or eliminating multiple chemotherapy-induced side effects, ALRN-6924 may improve patients’ quality of life and help them better tolerate chemotherapy. Enhanced tolerability may result in fewer dose reductions or delays of chemotherapy and the potential for improved efficacy.
Nearly 1 million patients in the U.S., across all cancer types, are diagnosed annually with p53-mutated cancer. Our vision is to bring selective chemoprotection to patients with p53-mutated cancers regardless of type of cancer or chemotherapy. Visit us at aileronrx.com to learn more.
| Investor Contacts: Richard Wanstall, SVP Chief Financial Officer Aileron Therapeutics 617-995-0900 rwanstall@aileronrx.com | Media Contact: Liz Melone 617-256-6622 lmelone@aileronrx.com |
| Hans C. Vitzthum LifeSci Advisors, LLC. 617-430-7578 hans@lifesciadvisors.com |
FAQ
What are the dates for Aileron Therapeutics' upcoming presentations?
What time will Aileron Therapeutics' presentation at the Emerging Growth Conference take place?
How can I access Aileron Therapeutics' presentation after the event?
What is ALRN-6924 and its significance for cancer patients?
How many patients are diagnosed with p53-mutated cancer in the U.S. annually?
